

World Association of Radiopharmaceutical & Molecular Therapy  
(WARMTH)

Kuwait Nuclear Medicine Council, Ministry of Health

International Workshop on Radionuclide Therapy And  
Annual Conference of Kuwait Society of Nuclear Medicine (KSNM)

Kuwait, 28-30 March 2011

Organised by

Kuwait Nuclear Medicine Council, Ministry of Health & Kuwait Society of Nuclear Medicine  
In Collaboration with  
Kuwait Institute for Medical Specializations (KIMS)

Introduction:

World Association of Radiopharmaceutical & Molecular Therapy (WARMTH) is an International Organization with stake holders from all fields of nuclear medicine and several allied clinical specialties, e.g., nuclear medicine physicians, radio-chemists, physicists, oncologists, rheumatologists, endocrinologists, Surgeons and Pathologists, who share research commitments to, and clinical practice in, therapeutic nuclear medicine. The major objectives of the WARMTH include setting standards for provision of radiopharmaceutical therapy, particularly in the development of uniform protocols for clinical practice of therapeutic nuclear medicine worldwide. Radionuclides are being used extensively to provide palliative and curative treatment in a number of benign and malignant diseases. The potential of radionuclides for treating malignant tumours has been recognized and put to use for the past several decades. It has been possible to exploit the physiology unique to an organ or a disease process to deliver the radionuclides selectively to the sites of abnormality. Radioiodine treatment of thyroid diseases (Thyroid cancer, Hyperthyroidism etc.), I-131 MIBG therapy of neuro-endocrine tumours, radio-immunotherapy of B-cell lymphoma, palliative treatment of metastatic bone pain, radiosynovectomy, etc. have all been established in therapeutic nuclear medicine. The use of Lu-177/Y-90 DOTA-TATE and Rhenium 188 labelled compounds is rapidly increasing, expanding the scope of therapeutic nuclear medicine.

To-day radiopharmaceutical therapy is the fastest growing branch of nuclear medicine. However, its practice in developing countries is only beginning to gain ground after years of trailing behind its use in the developed world. The establishment and consolidation of radiopharmaceutical therapy has come about as a result of a gradual change in the realization of its importance, cost-effectiveness and practicality. Availability of new generator produced radiopharmaceuticals like Re-188, PET tracers like Ga-68 for use in hospital radiopharmacy facilities has also enhanced the scope and practice of radionuclide therapy globally.

We have great pleasure in announcing the "International Workshop on Radionuclide Therapy (IWRT)", scheduled to be held at Kuwait from 28-30 March 2011 in conjunction with the Annual Conference of Kuwait Society of Nuclear Medicine.

Objectives:

The objectives of this workshop are to evaluate the current status of radiopharmaceutical therapy in general and to specifically address a few important procedures in detail; these include – radioiodine treatment of thyroid diseases, radionuclide treatment of neuro-endocrine tumours and radiosynovectomy in rheumatoid arthritis and haemophilic haemarthopathy. Leading International and National experts will participate in the workshop as faculty. This workshop is a part of WARMTH's objective of promoting radionuclide therapy in various regions of the world through organization of intensive and comprehensive training programs in selected areas of nuclear medicine therapy keeping in view the needs and priorities of the region.

The scope and Topics to be covered:

The workshop will cover topics and issues on all aspects of radiopharmaceutical therapy in general and topics related to Thyroid Cancer, Neuroendocrine Tumour and Radiosynovectomy in particular through a number of plenary lectures, scientific presentations, live demonstrations and workshops.

Oral & Poster Presentations:

Most of the Scientific Sessions will be devoted to lectures by Invited Faculty. A few Scientific Sessions will also be incorporated in the programme to enable the participants to present their scientific work through oral or poster presentations. Interested participants who would like to present papers are encouraged to submit their abstracts (Please see Form-C) latest by 31 December 2010. Results of abstract submission will be conveyed to all participants latest by 15 January 2011.

Expected results:

Through organization of this workshop we expect to accomplish the following: 1. To carry out an evaluation of the current status of radiopharmaceutical therapy in the region, 2. To help in the transfer of important information on the current trends in radiopharmaceutical therapy, 3. To train a number of professionals in nuclear medicine to carry out radionuclide therapy, 4. To promote radiopharmaceutical therapy globally in general, and in developing countries in particular.

Working Language:

The working language of the meeting will be English. All communications, synopses, abstracts and papers must be sent in English.

Visas

Participants who require a visa to enter Kuwait should submit the necessary application to the nearest diplomatic or consular representative of Kuwait as soon as possible.

Address for Communication:

(1) WARMTH Secretariat

Prof. A.K. Padhy  
Chairman, WARMTH  
Department of Nuclear Medicine & PET  
Block-2, Basement-1  
Singapore General Hospital  
Singapore – 169608  
Tel: +65 81287726  
Fax: Fax: +65-62240938  
E-mail: [ajitpadhy1@yahoo.co.uk](mailto:ajitpadhy1@yahoo.co.uk)

(2) Local Organizing Committee, Kuwait:

Prof. A H Elgazzar  
Chairman – Organizing Committee (IWRT)  
& Chairman Department of Nuclear Medicine  
Faculty of Nuclear Medicine  
University of Kuwait  
Kuwait  
Tel: +96597218735  
E-mail: [aelgazzar49@hotmail.com](mailto:aelgazzar49@hotmail.com)